Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Wnek

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Biotechnology Letters|January 7, 2009
Induction studies with Escherichia coli expressing recombinant interleukin-13 using multi-parameter flow cytometryJennifer O Shitu, John M Woodley, Richard Wnek, et al.
Cancer|August 19, 2020
First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumorsRavit Geva, Mark Voskoboynik, Konstantin Dobrenkov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid TumorsKyriakos P Papadopoulos, Karen Autio, Talia Golan, et al.
Cellular Immunology|June 1, 2005
Intra-thymic/splenic engraftment of human T cells in HLA-DR1 transgenic NOD/scid miceRamon E Camacho, Richard Wnek, Kashmira Shah, et al.
Experimental Hematology|July 31, 2007
Characterization of the NOD/scid-[Tg]DR1 mouse expressing HLA-DRB1*01 transgene: a model of SCID-hu mouse for vaccine developmentRamon E Camacho, Richard Wnek, Paul Fischer, et al.
The Journal of Biological Chemistry|July 9, 2002
Functional expression and characterization of macaque C-C chemokine receptor 3 (CCR3) and generation of potent antagonistic anti-macaque CCR3 monoclonal antibodiesLiwen Zhang, Marco P Soares, Yanfen Guan, et al.
Future Science OA|November 15, 2017
A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometryJinkai Teo, Anja Mirenska, Meihui Tan, et al.
American Journal of Respiratory and Critical Care Medicine|February 6, 2003
A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammationGloria C Koo, Kashmira Shah, Gloria J F Ding, et al.
Ebiomedicine|July 9, 2022
Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trialJonathan A Robbins, Dereck Tait, Qinlei Huang, et al.
Oncoimmunology|April 2, 2021
Combination of EP<sub>4</sub> antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cellsYun Wang, Long Cui, Peter Georgiev, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Biotechnology Letters|January 7, 2009
Induction studies with Escherichia coli expressing recombinant interleukin-13 using multi-parameter flow cytometryJennifer O Shitu, John M Woodley, Richard Wnek, et al.
Cancer|August 19, 2020
First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumorsRavit Geva, Mark Voskoboynik, Konstantin Dobrenkov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid TumorsKyriakos P Papadopoulos, Karen Autio, Talia Golan, et al.
Cellular Immunology|June 1, 2005
Intra-thymic/splenic engraftment of human T cells in HLA-DR1 transgenic NOD/scid miceRamon E Camacho, Richard Wnek, Kashmira Shah, et al.
Experimental Hematology|July 31, 2007
Characterization of the NOD/scid-[Tg]DR1 mouse expressing HLA-DRB1*01 transgene: a model of SCID-hu mouse for vaccine developmentRamon E Camacho, Richard Wnek, Paul Fischer, et al.
The Journal of Biological Chemistry|July 9, 2002
Functional expression and characterization of macaque C-C chemokine receptor 3 (CCR3) and generation of potent antagonistic anti-macaque CCR3 monoclonal antibodiesLiwen Zhang, Marco P Soares, Yanfen Guan, et al.
Future Science OA|November 15, 2017
A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometryJinkai Teo, Anja Mirenska, Meihui Tan, et al.
American Journal of Respiratory and Critical Care Medicine|February 6, 2003
A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammationGloria C Koo, Kashmira Shah, Gloria J F Ding, et al.
Ebiomedicine|July 9, 2022
Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trialJonathan A Robbins, Dereck Tait, Qinlei Huang, et al.
Oncoimmunology|April 2, 2021
Combination of EP<sub>4</sub> antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cellsYun Wang, Long Cui, Peter Georgiev, et al.
Pageof 2